Adjuvant CDK4/6 Inhibition in Early Breast Cancer: Interpreting NATALEE and monarchE

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join breast medical oncologists Matthew Kurian and Komal Jhaveri as they discuss the latest advancements in adjuvant CDK4-6 inhibitors and their implications for breast cancer treatment. In this episode, they delve into the five-year data from the NATALY study, comparing it with findings from the Abemocyclid trials and the Monarch E study.
Key topics include:
• The significance of the NATALY study's findings for node-negative and high-risk patient populations.
• Insights into managing N1 patients and the complexities of ER-positive breast cancer.
• A discussion on the emerging role of oral SERDs in the adjuvant setting and their potential impact on treatment strategies.
Tune in for an engaging conversation that highlights the evolving landscape of breast cancer therapy and the importance of patient-physician collaboration in treatment decisions.

Website: https://oncupdates.com/
Mail: [email protected]
X/twitter: https://x.com/OncUpdatesBreast cancer, oncology, medical oncology, adjuvant therapy, CDK4/6 inhibitors, ribociclib, Kisqali, abemaciclib, Verzenio, NATALEE trial, NATALY study, monarchE trial, early breast cancer, HR+ breast cancer, HER2- breast cancer, node negative breast cancer, high risk breast cancer, N1 breast cancer, ER positive breast cancer, oral SERD, elacestrant, Orserdu, patient-physician collaboration, treatment decisions, breast cancer treatment, Matthew Kurian, Komal Jhaveri, medical podcast, oncology podcast, breast cancer updates, five-year data, breast cancer specialists


Don't forget to like, subscribe, and share your thoughts in the comments!

#BreastCancer #Oncology #CDK46Inhibitors #NATALYStudy #OralSERDs #MedicalPodcast
Categoria
Oncology
Commenta per primo questo video.

Prossimo